Clarametyx Biosciences is a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases. Its lead program, CMTX-101, is an investigational antibody therapy designed to rapidly destroy the pro-inflammatory structure of bacterial biofilms to enhance antibiotic and immune efficacy and is being developed in cystic fibrosis. CMTX-101 is in a Phase 1b/2a trial evaluating safety, tolerability, pharmacokinetics, immunogenicity and reduction of pulmonary Pseudomonas aeruginosa burden; an interim analysis of the first 21 participants met prespecified criteria to proceed. The company is also advancing an anti-biofilm vaccine, CMTX-301, in early development and is pursuing lead optimization toward a 2027 IND. Clarametyx has closed an upsized second tranche of its Series A financing from existing investors to support ongoing pipeline activities for both therapeutic and vaccine programs. The Phase 1b/2a study is on track for full enrollment by the end of 2025, and additional participants and sites will be added. The company is based in Columbus, Ohio. Clarametyx Biosciences develops a technology platform that targets bacterial biofilms to enable a more effective immune response and antibiotic interventions. The company is building a pipeline of immune-enabling therapies and vaccines for serious bacterial infections associated with biofilms, with a near-term focus on chronic respiratory diseases. Its lead programs include CMTX-101, currently in a trial for cystic fibrosis–related infections conducted in collaboration with the Cystic Fibrosis Foundation, and CMTX-301, a vaccine program recently funded by CARB-X. The company is clinical stage and led by CEO David Richards. Clarametyx intends to use new funding to accelerate the ongoing CMTX-101 trial and advance development of CMTX-301. The company is based in Columbus, OH. Clarametyx Biosciences is a clinical-stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with bacterial biofilms. Launched in 2020 to advance an antibody technology licensed from Nationwide Children’s Hospital, the platform is non-antibiotic and pathogen-agnostic, designed to target and remove universal structural elements within biofilms to induce rapid biofilm collapse. Its lead candidate, CMTX-101, is being developed as an adjunct to standard-of-care antibiotics to render bacteria vulnerable to immune or antibiotic intervention. The company is evaluating its anti-biofilm technology in both therapeutic and preventive settings and is building a pipeline with a near-term focus on challenging respiratory infections. Clarametyx has initiated a Phase 1b/2a trial in people with cystic fibrosis to assess safety, tolerability, PK, immunogenicity, reduction of pulmonary P. aeruginosa burden, and exploratory endpoints (ClinicalTrials.gov identifier NCT06159725). The recently completed $33 million Series A will fund accelerated pipeline work and expanded clinical evaluations; the company is based in Columbus, Ohio. Clarametyx Biosciences is developing a platform that targets the biofilm matrix to remove a universal, pathogen-agnostic target, collapsing the protective shield and rendering bacteria vulnerable to immune and antibiotic attack. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development with a first targeted indication of moderate-to-severe or hospital-acquired pneumonia. The company is advancing IND-enabling activities including a GLP toxicity study and Phase 1 material production, with plans to initiate first-in-human clinical trials later this year. Financially, Clarametyx has received earlier CARB-X awards in 2020 and 2021 and was recently awarded an additional $3.89 million in option funding to accelerate development of CMTX-101. Under the CARB-X agreement the company is eligible for one further funding option to support a first-in-human trial, contingent on milestone achievement and competitive positioning. Clarametyx is building a broader pipeline of immune-enabling therapies and vaccines for life-threatening infections associated with biofilms. Clarametyx Biosciences is a preclinical-stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent, biofilm-associated bacterial infections. Its platform is designed to precisely remove a universal, pathogen-agnostic target within the biofilm extracellular matrix, rapidly collapsing the protective shield and sensitizing bacteria to immune and antibiotic attack. The approach aims to enhance innate immune activity and sensitize a wide range of Gram-negative and Gram-positive pathogens to first-line and other antibiotics, enabling potential therapeutics and vaccines. Lead candidate CMTX-101 is a humanized monoclonal antibody in preclinical development for hospital-acquired, moderate-to-severe pneumonia to be co-administered with standard antibiotic regimens. Clarametyx was awarded up to $14.2 million from CARB-X to advance its platform through completion of a Phase 1 clinical study, with a $2.4M base period and three milestone-based options. The company is based in Columbus, Ohio and is building a pipeline of immune-enabling therapies and vaccines for life-threatening infections associated with biofilms.

Total raised

$51M

Funding rounds

6

Latest round

Series A

Latest activity

Jan 2024